U.S. Markets close in 5 hrs 49 mins

Investors Who Bought Conatus Pharmaceuticals (NASDAQ:CNAT) Shares Five Years Ago Are Now Down 96%

Simply Wall St

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shareholders should be happy to see the share price up 21% in the last month. But will that repair the damage for the weary investors who have owned this stock as it declined over half a decade? Probably not. Indeed, the share price is down a whopping 96% in that time. While the recent increase might be a green shoot, we're certainly hesitant to rejoice. The million dollar question is whether the company can justify a long term recovery.

We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.

View our latest analysis for Conatus Pharmaceuticals

Because Conatus Pharmaceuticals is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.


The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

NasdaqGM:CNAT Income Statement, July 25th 2019

If you are thinking of buying or selling Conatus Pharmaceuticals stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

While the broader market gained around 6.5% in the last year, Conatus Pharmaceuticals shareholders lost 92%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 46% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. You might want to assess this data-rich visualization of its earnings, revenue and cash flow.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.